Sri Lanka
Tuberculosis profile
Population  2013 21 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.3 (0.99–1.6) 5.9 (4.7–7.3)
Mortality (HIV+TB only) <0.01 (<0.01–0.01) 0.03 (0.01–0.05)
Prevalence  (includes HIV+TB) 22 (11–36) 103 (53–170)
Incidence  (includes HIV+TB) 14 (13–16) 66 (59–75)
Incidence (HIV+TB only) 0.025 (<0.01–0.047) 0.12 (0.04–0.22)
Case detection, all forms (%) 66 (59–74)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.2 (0–1) 0.58 (0.07–2.1)
MDR-TB cases among notified pulmonary
TB cases
13 (0–65) 2 (0–9)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 4 459   243
Pulmonary, clinically diagnosed 2 040   0
Extrapulmonary 2 589   0
       
Total new and relapse 9 331    
Previously treated, excluding relapses 167    
Total cases notified 9 498    
Among 9 010 new and relapse cases:
310 (3%) cases aged under 15 years; male:female ratio: 2.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 920 (21%) 404 (99%) 1 329
Laboratory-confirmed RR-/MDR-TB cases     12
Patients started on MDR-TB treatment     4
TB/HIV 2013 Number (%)
TB patients with known HIV status 4 650 (49)
HIV-positive TB patients 37 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 37 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 37 (100)
HIV-positive people screened for TB 665  
HIV-positive people provided with IPT 9  
Treatment success rate (%)
New cases registered in 2012 86
Previously treated cases registered in 2012 59
HIV-positive TB cases, all types, registered in 2012 18
RR-/MDR-TB cases started on second-line treatment in 2011 83
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 11
% Funded domestically 49%
% Funded internationally 21%
% Unfunded 31%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-28 Data: www.who.int/tb/data